Camrelizumab Plus Apatinib in Extensive-Stage SCLC (PASSION): A Multicenter, Two-Stage, Phase 2 Trial
Open accessAbstract
Introduction Treatment options in the second-line extensive-stage SCLC (ED-SCLC) setting are limited. The PASSION study (ClinicalTrials.gov identifier: NCT03417895) was a phase 2 study of camrelizumab plus apatinib in ED-SCLC after platinum-based chemotherapy.Methods In stage I of the study, patients were randomized (1:1:1) to receive camrelizumab 200 mg every 2 weeks plus apatinib 375 mg once daily (QD), 5 days on and 2 days off, or 7 days on and 7 days off (six patients each cohort). On the basis of tolerability during the first 28-day cycle and efficacy data at stage I, one cohort was chosen to expand to 45 patients at stage II. The primary end point was objective response rate (ORR).Results From April 20, 2018 to March 12, 2019, a total of 59 patients were enrolled, with 47 patients in the QD cohort. In the QD cohort, confirmed ORR reached 34.0% (95% confidence interval: 20.9‒49.3), the median progression-free survival was 3.6 months, and the median overall survival was 8.4 months. Chemotherapy-sensitive and chemotherapy-resistant patients (defined as patients with disease relapse at ≥90 and <90 d after platinum-based chemotherapy, respectively) had comparable confirmed ORR (37.5% versus 32.3%), median progression-free survival (3.6 versus 2.7 mo), and median overall survival (9.6 versus 8.0 mo). Treatment-related adverse events of grade 3 or higher were reported in 43 of 59 patients (72.9%). Five patients (8.5%) discontinued because of treatment-related adverse events.Conclusions Camrelizumab plus apatinib exhibited potential antitumor activity in patients with both chemotherapy-sensitive and chemotherapy-resistant ED-SCLC who had failed platinum-based chemotherapy with an acceptable toxicity profile. This phase 2 data warrant further clinical studies of camrelizumab plus apatinib in SCLC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305, camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers.
“Combination therapies such as sintilimab plus anlotinib, sintilimab plus IBI305 (bevacizumab biosimilar), camrelizumab plus apatinib, and toripalimab plus axitinib demonstrated potent antitumor effects in multiple types of cancers [22, 114–120].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [117]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109 · see citing works
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma
Finn, R. S., Qin, S., Ikeda, M., Galle, P. R., Ducreux, M., Kim, T.-Y., Kudo, M., Breder, V., Merle, P., Kaseb, A. O., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915745 · Cited by 7,470 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · see citing works
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586 · see citing works
Paz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298 · see citing works
Self-citationKerbel, R. S. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0706596 · Cited by 1,962 · see citing works
Govindan, R., Page, N. C., Morgensztern, D., Read, W. L., Tierney, R. M., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. F. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,844 · see citing works
Improved Survival with Bevacizumab in Advanced Cervical Cancer
Tewari, K. S., Sill, M. W., Long, H. J., Penson, R. T., Huang, H. Q., Ramondetta, L. M., Landrum, L. M., Oaknin, A., Reid, T. J. A., Leitão, M. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1309748 · Cited by 1,510 · see citing works
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · see citing works
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062 · see citing works
Rini, B. I., Powles, T. B., Atkins, M. B., Escudier, B. J., McDermott, D. F., Suárez, C., Sergio Bracarda, A., Stadler, W. M., Donskov, F. N., Lee, J., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30723-8 · Cited by 991 · see citing works
Li, J., Qin, S., Xu, J., Xiong, J., Wu, C., Bai, Y., Liu, W., Tong, J., Liu, Y., Xu, R., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.5995 · Cited by 975 · see citing works
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., CLARK, P. I., Palmer, M., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968 · see citing works
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 892 · see citing works
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669 · see citing works
Targeting VEGF/VEGFR to modulate antitumor immunity
Yang, J., Yan, J., & Liu, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00978 · Cited by 646 · see citing works
Qin, S., Ren, Z., Meng, Z., Chen, Z., Chai, X., Xiong, J., Bai, Y., Yang, L., Zhu, H., Fang, W. J., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30011-5 · Cited by 604 · see citing works
Self-citationEffect of cigarette smoking on major histological types of lung cancer: a meta-analysis
Khuder, S. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00181-1 · Cited by 521 · see citing works
Ott, P. A., Élez, E., Hiret, S., Kim, D., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 520 · see citing works
Pesch, B., Kendzia, B., Gustavsson, P., Jöckel, K., Johnen, G., Pohlabeln, H., Olsson, A., Ahrens, W., Gross, I. M., Brüske, I., et al. (2012) · International Journal of Cancer · doi:10.1002/ijc.27339 · Cited by 509 · see citing works
Xu, J., Zhang, Y., Jia, R., Yue, C., Chang, L., Liu, R., Zhang, G., Zhao, C., Zhang, Y., Chen, C., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2484 · Cited by 498 · see citing works
Self-citationFang, W., Yang, Y., Ma, Y., Hong, S., Lin, L., He, X., Xiong, J., Li, P., Zhao, H., Huang, Y., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30495-9 · Cited by 489 · see citing works
Trigo, J. M., Subbiah, V., Besse, B., Moreno, V., López‐López, R., Sala, M. Á., Peters, S., Ponce, S., Fernández, C., Alfaro, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30068-1 · Cited by 489 · see citing works
Ardizzoni, A., Hansen, H., Dombernowsky, P., Gamucci, T., Kaplan, S., Postmus, P. E., Giaccone, G., Schaefer, B., Wanders, J., & Verweij, J. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.5.2090 · Cited by 480 · see citing works
Chung, H. C., Piha-Paul, S. A., Lopez-Martin, J. A., Schellens, J. H. M., Kao, S. C.-H., Miller, W. H., Delord, J., Gao, B., Planchard, D., Gottfried, M., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.12.109 · Cited by 409 · see citing works
von Pawel, J., Jotte, R. M., Spigel, D. R., O'Brien, M. E. R., Socinski, M. A., Mezger, J. M., Steins, M. B., Bosquée, L., Bubis, J. A., Nackaerts, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5392 · Cited by 352 · see citing works
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 320 · see citing works
Self-citationHuang, J., Xu, B., Mo, H., Zhang, W., Chen, X., Wu, D., Qu, D., Wang, X., Lan, B., Yang, B., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2439 · Cited by 201 · see citing works
Ou, S. I., Ziogas, A., & Zell, J. A. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31819140fb · Cited by 164 · see citing works
Song, Y., Wu, J., Chen, X., Lin, T., Cao, J., Liu, Y., Zhao, Y., Jin, J., Huang, H., Hu, J., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1680 · Cited by 150 · see citing works
Treatment for small cell lung cancer, where are we now?-a review.
Alvarado-Luna, G., & Morales-Espinosa, D. (2016) · Europe PMC (PubMed Central) · doi:10.3978/j.issn.2218-6751.2016.01.13 · Cited by 142 · see citing works
Xuelian, C., Ma, L., Wang, X., Mo, H., Wu, D., Bo, L., Qu, D., Zhang, H., Jing, H., & Xu, B. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0172 · Cited by 68 · see citing works
Effect of cigarette smoking on major histological types of lung cancer in men
Khuder, S., Dayal, H. H., Mutgi, A. B., Willey, J. C., & Dayal, G. (1998) · Lung Cancer · doi:10.1016/s0169-5002(98)00068-3 · Cited by 60 · see citing works
Xu, Y., Huang, Z., Lu, H., Yu, X., Li, Y., Li, W., Chen, J., Chen, M., Gong, L., Chen, K., et al. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0583-6 · Cited by 51 · see citing works
Self-citationLiu, X., Jiang, T., Li, W., Li, X., Zhao, C., Shi, J., Zhao, S., Jia, Y., Qiao, M., Zhang, L., et al. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.11.022 · Cited by 44 · see citing works
Self-citationLiu, Y., Hu, X., Jiang, J., Yang, L., Zhou, S., Liu, P., Li, J., Wang, Y., Hao, X., & Shi, Y. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0391 · Cited by 24 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Combination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445 · see citing works
Cheng, Y., Han, L., Wu, L., Chen, J., Sun, H., Wen, G., Ji, Y., Dvorkin, M., Shi, J., Pan, Z., et al. (2022) · JAMA · doi:10.1001/jama.2022.16464 · Cited by 492 · see citing works
Self-citationTyrosine kinase inhibitors for solid tumors in the past 20 years (2001–2020)
Huang, L., Jiang, S., & Shi, Y. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00977-0 · Cited by 467 · see citing works
Wang, J., Zhou, C., Yao, W., Wang, Q., Min, X., Chen, G., Xu, X., Li, X., Xu, F., Fang, Y., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(22)00224-8 · Cited by 430 · see citing works
Self-citationNew clinical trial design in precision medicine: discovery, development and direction
Duan, X.-P., Qin, B., Jiao, X., Liu, K., Wang, Z., & Zang, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01760-0 · Cited by 217 · see citing works
Self-citationZhang, Z., Wu, B., Peng, G., Xiao, G., Huang, J., Ding, Q., Yang, C., Xiong, X., Ma, H., Shi, L., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0666 · Cited by 160 · see citing works
Self-citationEvolving landscape of PD-L2: bring new light to checkpoint immunotherapy
Wang, Y., Du, J., Gao, Z., Sun, H., Mei, M., Wang, Y., Ren, Y., & Zhou, X. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02084-y · Cited by 112 · see citing works
Niu, M., Yi, M., Wu, Y., Lyu, L., He, Q., Yang, R., Zeng, L., Shi, J. Y., Zhang, J., Zhou, P., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01487-5 · Cited by 106 · see citing works
Self-citationCheng, H., Zong, L., Kong, Y., Wang, X., Gu, Y. L., Cang, W., Zhao, J., Wan, X., Yang, J., & Xiang, Y. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00460-5 · Cited by 90 · see citing works
Self-citationMeng, X., Wu, T., Hong, Y., Fan, Q., Ren, Z., Guo, Y., Yang, X., Shi, P., Yang, J., Yin, X., et al. (2022) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(21)00378-2 · Cited by 87 · see citing works
Self-citationZhou, Y.-J., Li, G., Wang, J., Liu, M., Wang, Z., Song, Y., Zhang, X., & Wang, X. (2023) · Blood Science · doi:10.1097/bs9.0000000000000149 · Cited by 85 · see citing works
Self-citationToripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer
Cheng, Y., Zhang, W., Wu, L., Zhou, C., Wang, D., Xia, B., Bi, M., Fu, X., Li, C., Lv, D., et al. (2024) · JAMA Oncology · doi:10.1001/jamaoncol.2024.5019 · Cited by 72 · see citing works
Self-citationAngiogenesis Inhibitors in Small Cell Lung Cancer
Montanino, A., Manzo, A., Carillio, G., Palumbo, G., Esposito, G., Sforza, V., Costanzo, R., Sandomenico, C., Botti, G., Piccirillo, M. C., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.655316 · Cited by 67 · see citing works
Caliman, E., Fancelli, S., Petroni, G., Michelet, M. R. G., Cosso, F., Ottanelli, C., Mazzoni, F., Voltolini, L., Pillozzi, S., & Antonuzzo, L. (2022) · Lung Cancer · doi:10.1016/j.lungcan.2022.11.014 · Cited by 53 · see citing works
Cai, H., Xu, B., Li, N., Zheng, B., Zheng, Z., & Liu, M. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.732912 · Cited by 36 · see citing works
SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
Belluomini, L., Calvetti, L., Inno, A., Pasello, G., Roca, E., Vattemi, E., Veccia, A., Menis, J., & Pilotto, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.840783 · Cited by 35 · see citing works
Yu, L., Xu, J., Qiao, R., Han, B., Zhong, H., & Zhong, R. (2022) · Cancer Medicine · doi:10.1002/cam4.5360 · Cited by 34 · see citing works
Extensive‐stage small‐cell lung cancer: Current management and future directions
Yu, Y., Chen, K., & Fan, Y. (2022) · International Journal of Cancer · doi:10.1002/ijc.34346 · Cited by 33 · see citing works
Self-citationEfficacy and Response Biomarkers of Apatinib in the Treatment of Malignancies in China: A Review
Tian, Z., Niu, X., & Yao, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.749083 · Cited by 32 · see citing works
Han, X., Guo, J., Li, L., Huang, Y., Meng, X., Wang, L., Zhu, H., Meng, X., Shao, Q., Li, X., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01957-3 · Cited by 30 · see citing works
Self-citationResearch progress in immune checkpoint inhibitors for lung cancer in China
Gan, J., Huang, Y., Fang, W., & Zhang, L. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359211029826 · Cited by 27 · see citing works
Wang, X., Wu, X., Yang, Y., Xu, W., Tian, H., Lian, B., Chi, Z., Si, L., Sheng, X., Kong, Y., et al. (2023) · European Journal of Cancer · doi:10.1016/j.ejca.2022.12.027 · Cited by 29 · see citing works
Chen, T., Wang, M., Chen, Y., Cao, Y., & Liu, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01283-9 · Cited by 28 · see citing works
Immunotherapy-Related Cystitis: Case Report and Review of the Literature
Zhu, L., Wang, Z., Stebbing, J., Wang, Z., & Peng, L. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s321965 · Cited by 28 · see citing works
Self-citationStarzer, A. M., Wolff, L., Popov, P., Kiesewetter, B., Preusser, M., & Berghoff, A. S. (2024) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2024.102718 · Cited by 27 · see citing works
Yu, L., Hu, Y., Xu, J., Qiao, R., Zhong, H., Han, B., Xia, J., & Zhong, R. (2023) · International Journal of Cancer · doi:10.1002/ijc.34536 · Cited by 26 · see citing works
Self-citationGlobal research landscape and trends of lung cancer immunotherapy: A bibliometric analysis
Liu, Y., Xu, C., Han, X., Cheng, X., Jiang, S., Lin, Y., Zhang, Z., Lu, L., Qu, B., Chen, Y., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1032747 · Cited by 26 · see citing works
Ma, S., He, Z., Liu, Y., Wang, L., Yang, S., Wu, Y., Chen, H., Wu, Y., & Wang, Q. (2024) · EClinicalMedicine · doi:10.1016/j.eclinm.2024.102543 · Cited by 25 · see citing works
Self-citationBernabé, R., Chen, Y., Dowlati, A., & Eason, P. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2023.01.012 · Cited by 23 · see citing works
Wu, S., Wu, S., Liao, X., Zhou, C., Qiu, F. X., Wang, C., & Zhong, W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1274937 · Cited by 22 · see citing works
Self-citationLiu, M., Qiu, G., Guan, W., Xiaohong, X., Lin, X., Xie, Z., Zhang, J., Qin, Y., Du, H., Chen, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02153-7 · Cited by 21 · see citing works
Self-citationWu, J., Song, Y., Chen, X., Lin, T., Cao, J., Liu, Y., Zhao, Y., Jin, J., Huang, H., Hu, J., et al. (2021) · International Journal of Cancer · doi:10.1002/ijc.33852 · Cited by 21 · see citing works
Small cell lung cancer: emerging subtypes, signaling pathways, and therapeutic vulnerabilities
Zhang, J., Zeng, X., Guo, Q., Sheng, Z., Chen, Y., Wan, S., Zhang, L., & Zhang, P. (2024) · Experimental Hematology and Oncology · doi:10.1186/s40164-024-00548-w · Cited by 19 · see citing works
Li, L., Wen, Q., & Ding, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.905520 · Cited by 19 · see citing works
Yang, Y., Ai, X., Xu, H., Yang, G., Yang, L., Hao, X., Yang, K., Mi, Y., Wang, G., Zhang, S., et al. (2022) · Thoracic Cancer · doi:10.1111/1759-7714.14684 · Cited by 19 · see citing works
CACA guidelines for holistic integrative management of lung cancer
Wang, J. (2024) · Holistic Integrative Oncology · doi:10.1007/s44178-024-00069-w · Cited by 18 · see citing works
Self-citationZhu, Y., Wei, Z., Wang, J., Pei, Y., Jin, J., Dong, L., Li, Z.-H., Liu, Z., Yu, M., Li, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-54661-9 · Cited by 20 · see citing works
Self-citationHao, Y., Qiao, Y.-P., & Cheng, J.-D. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s337316 · Cited by 17 · see citing works
Lorenzi, M., Resi, M. V., Bonanno, L., Frega, S., Maso, A. D., Ferro, A., Guarneri, V., & Pasello, G. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1308109 · Cited by 17 · see citing works
Liu, Q., Xu, J.-Y., Xu, Y.-H., Chen, M., Deng, L., Wu, J., Zhou, T., Zhang, L., Tan, J., Pu, X., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-313 · Cited by 16 · see citing works
Self-citationSmall cell lung cancer with liver metastases: from underlying mechanisms to treatment strategies
Fan, L., Lin, Y., Fu, Y., & Wang, J. (2024) · Cancer and Metastasis Reviews · doi:10.1007/s10555-024-10220-8 · Cited by 17 · see citing works
Self-citationAkamatsu, H., Teraoka, S., Hayashi, H., Fujimoto, D., Hayata, A., Haratani, K., Ozawa, Y., Yoshida, T., Iwasa, T., Shimokawa, T., et al. (2021) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2021.100184 · Cited by 16 · see citing works
Liu, X., Xing, H., & Liu, B. (2022) · PubMed Central · Cited by 16 · see citing works
Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
Wang, Z., Huang, Y., Long, L., Zhou, L. Q., Huang, Y., Gan, L., Pu, A., Li, S., & Xie, R. (2021) · Journal of Ovarian Research · doi:10.1186/s13048-021-00843-8 · Cited by 15 · see citing works
Self-citationNi, J., Si, X., Wang, H., Zhang, X., & Zhang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1168879 · Cited by 15 · see citing works
Neurological adverse events associated with PD-1/PD-L1 immune checkpoint inhibitors
Zhou, Y., & Li, H. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1227049 · Cited by 15 · see citing works
Qu, W., Wang, F., Qin, S., Sun, Y., & Huang, C. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241242607 · Cited by 15 · see citing works
Liao, L., Cen, B., Li, G., Wei, Y., Wang, Z., Huang, W., He, S., Yuan, Y., & Ji, A. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1937381 · Cited by 13 · see citing works
Self-citationWang, J., Su, S., Li, J., & Li, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.695512 · Cited by 12 · see citing works
Self-citationWang, J., Gao, S., Yang, Y., Liu, X., Zhang, P., Dong, S., Wang, X., & Yao, W. (2021) · Cancer Management and Research · doi:10.2147/cmar.s337253 · Cited by 12 · see citing works
Self-citationHe, L., Pi, Y., Li, Y., Wu, Y., Jiang, J., Rong, X., Cai, J., Yue, Z., Cheng, J., Li, H., et al. (2022) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2022.03.027 · Cited by 12 · see citing works
Zhang, Z., Li, Y., Dong, Y., Li, J., Zhang, B., Zhang, C., & Cui, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.846597 · Cited by 12 · see citing works
State of the art in treatment of small cell lung cancer
Behrouzi, R., & Blackhall, F. H. (2025) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359251363518 · Cited by 11 · see citing works
Yang, G., Sun, H., Sun, N., Huang, W., Wang, Z., Zhang, H., & Liu, C. (2022) · Journal of Thoracic Disease · doi:10.21037/jtd-22-1682 · Cited by 11 · see citing works
Self-citationJiang, Y., Zhang, L., Zhu, F., Zhu, H., Cao, X., & Zhang, Y. (2022) · Annals of Palliative Medicine · doi:10.21037/apm-21-3860 · Cited by 11 · see citing works
Li, J., Zhang, X., Mu, Z., Sun, D., Sun, Y., & Lin, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.943916 · Cited by 11 · see citing works
Zhou, H. K., Wang, Y., Lin, Y., Cai, W., Li, X., & He, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.774445 · Cited by 10 · see citing works
Self-citationWang, L., Li, X., Cheng, Y., Yang, J., Liu, S., Ma, T., Luo, L., Hu, Y., Cai, Y., & Yan, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.784861 · Cited by 10 · see citing works
Self-citationXu, Z., Zhang, Y., & Yu, Y. (2021) · Annals of Palliative Medicine · doi:10.21037/apm-20-2275 · Cited by 10 · see citing works
Chen, C., Chen, M., Bai, Y., Li, Y., Peng, J., Yao, B., Feng, J., Zhou, J., & Ma, H. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241249690 · Cited by 9 · see citing works
Self-citationLiu, Q., Zhang, Y., Liu, M., Xu, R., Yi, F., Wei, Y., Zhu, S., & Zhang, W. (2021) · World Journal of Surgical Oncology · doi:10.1186/s12957-021-02410-3 · Cited by 9 · see citing works
Immunotherapy for small cell lung cancer: the current state and future trajectories
Qiang, M., Liu, H., Yang, L., Wang, H., & Guo, R. (2024) · Discover Oncology · doi:10.1007/s12672-024-01119-5 · Cited by 9 · see citing works
Treatment of small cell lung cancer: recent advances
Chu, X., Han, C., & Su, C. (2021) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000804 · Cited by 8 · see citing works
Shen, S., Li, X., Guo, S., Xu, L., & Yan, N. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1391828 · Cited by 7 · see citing works
Self-citationZhao, J., Zhuo, X., Liu, L., Yang, Z., & Fu, G. (2022) · Cancer Innovation · doi:10.1002/cai2.23 · Cited by 7 · see citing works
Self-citationZhang, Y., Cui, Y., Li, Y., & Cong, L. (2023) · Medicina · doi:10.3390/medicina59020215 · Cited by 7 · see citing works
Novel therapeutic strategies for recurrent SCLC
Moliner, L., Zhang, B., Lamberti, G., Ardizzoni, A., Byers, L. A., & Califano, R. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104017 · Cited by 7 · see citing works
The Evolving Scenario of ES-SCLC Management: From Biology to New Cancer Therapeutics
Aliaga, P. T., Signore, E. D., Fuorivia, V., Spitaleri, G., Asnaghi, R., Attili, I., Corvaja, C., Schianca, A. C., Passaro, A., & de Marinis, F. (2024) · Genes · doi:10.3390/genes15060701 · Cited by 6 · see citing works
Big Decisions on Small Cell Lung Cancer: A Focus on Clinical Care Updates and Patient Perspectives
Xiao, W., & Chiang, A. C. (2024) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_432520 · Cited by 6 · see citing works
Liu, F., Yin, G., Tao, Y., & Pan, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114372 · Cited by 6 · see citing works
Zheng, Y., Dong, H., Yu, Y., Hu, Z., Xue, C., Zhang, X., & Cui, H. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.110785 · Cited by 6 · see citing works
Liu, K., Bao, J.-F., Wang, T., Yang, H., & Xu, B. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i18.6198 · Cited by 6 · see citing works
Self-citationMechanisms of immunotherapy resistance in small cell lung cancer
Nie, Y., Schalper, K. A., & Chiang, A. C. (2024) · Cancer Drug Resistance · doi:10.20517/cdr.2024.154 · Cited by 5 · see citing works
Zhang, J., Wu, Z., Wang, S., Sun, Y., Wu, J., Wang, D., Ge, Y., Li, J., Sun, H., Cheng, Q., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14458-5 · Cited by 5 · see citing works
Liu, Z., Zheng, Z., Dong, L., Guo, X., Jia, X., Wang, J., Meng, L., Cui, X., & Jiang, X. M. (2022) · Scientific Reports · doi:10.1038/s41598-022-20272-x · Cited by 5 · see citing works
Self-citationLiu, Y., Song, Y., Zuo, S., Zhang, X., Liu, H., Wang, J., Wang, J., Tang, Y., Zheng, W., Ying, Z., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1128172 · Cited by 5 · see citing works
Self-citationZhou, L., Xu, G., Chen, T., Wang, Q., Zhao, J., Zhang, T., Duan, R., & Xia, Y. (2023) · Cancer Reports · doi:10.1002/cnr2.1855 · Cited by 5 · see citing works
Self-citationCarrelizumab combined with anlotinib in the treatment of extensive-stage small cell lung cancer
Liu, L., Zhang, X., Zhou, L., Yang, T., Qiao, Y., & Jiang, X. (2021) · Medicine · doi:10.1097/md.0000000000027138 · Cited by 5 · see citing works
Sheng, Z.-K., Liu, Y., Du, L., Zhang, S., Zhang, A.-Y., Xie, H.-J., Lin, H., Yan, B.-L., Xue, M., Ruan, Z.-X., et al. (2024) · RSC Advances · doi:10.1039/d3ra07201k · Cited by 5 · see citing works
Gao, G., Sun, M., Yang, Z., Li, J., Ji, H., & Yu, G. (2025) · Technology in Cancer Research & Treatment · doi:10.1177/15330338251329248 · Cited by 4 · see citing works
Yang, H., Yang, L., Liu, Y., & Wang, L. (2025) · Biologics · doi:10.2147/btt.s500470 · Cited by 4 · see citing works
Self-citationChen, T., Li, Z., Zhao, H., & Yang, R. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s525481 · Cited by 4 · see citing works
Small-Cell Lung Cancer Updates
Nie, Y., & Chiang, A. C. (2025) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/a-2649-9240 · Cited by 4 · see citing works
Yan, J., Wang, Y.-Z., Zhao, S.-Y., Na, F., Cui, Z.-X., Cai, L.-T., Li, H.-M., & Zhao, M. (2026) · Cancer Letters · doi:10.1016/j.canlet.2026.218382 · Cited by 4 · see citing works
Actionable Driver Events in Small Cell Lung Cancer
Gutiérrez, M., Zamora, I., Freeman, M. R., Encı́o, I., & Rotinen, M. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms25010105 · Cited by 4 · see citing works
Qu, Y., Abulimiti, M., Zhou, N., Keyoumu, S., Bulibu, J., Wang, W. T., Tang, X.-S., Li, N., Li, J., Wang, P., et al. (2024) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-610 · Cited by 4 · see citing works
Zhao, L., Zhao, Z., Yan, X., Hu, X., Feng, J., & Yu, S. (2024) · Technology in Cancer Research & Treatment · doi:10.1177/15330338241227055 · Cited by 4 · see citing works
Li, S., Yu, Z., Liu, H., Li, S., Wang, M., Ning, F., & Tian, L. (2024) · Cancer Medicine · doi:10.1002/cam4.7349 · Cited by 3 · see citing works
Zhou, X., Yan, X., & Wu, Y. F. (2024) · Biomedical Reports · doi:10.3892/br.2024.1743 · Cited by 3 · see citing works
Zuo, L., Jing, L., Hu, N., & Chen, R. (2024) · BMC Cancer · doi:10.1186/s12885-024-13118-4 · Cited by 3 · see citing works
Xiong, J., & Xia, L. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2024.1462581 · Cited by 3 · see citing works
Zhang, D., Kong, F., Gao, F., Li, L., Liang, Y., Yu, M., Zhao, L., Wang, N., & Jia, Y. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22913 · Cited by 3 · see citing works
Song, L., Fang, X., Jiang, P., Li, Y., Li, X., Xu, X., Liang, Y., Li, C., & Zheng, Y. (2023) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo-23-741 · Cited by 3 · see citing works
Self-citationXie, Q. R., Zheng, H., Su, N., & Li, Q. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061592 · Cited by 3 · see citing works
Tian, J., Sui, L., Wang, H., & Chen, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1180735 · Cited by 3 · see citing works
Wang, J., Liang, S., Xu, L. L., Kong, Y., Seki, N., Ganti, A. K., Neal, J. W., Li, J., Xu, F., Li, K., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-769 · Cited by 2 · see citing works
Self-citationChi, X., Dong, Y., Zhu, L., Su, D., & Wu, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1693401 · Cited by 2 · see citing works
Wang, H., Wang, X., Jiang, S., Zhu, J., Liu, J., Zhou, C., Zhu, Y., & Han, Y. P. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.956372 · Cited by 2 · see citing works
Self-citationZhou, J., Du, Z., Liang, Y., & Zhang, S. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104222 · Cited by 2 · see citing works
Self-citationWu, Y., Zhang, Y., Tian, Y., Lv, Y., & Zhang, J. (2024) · Clinical & Translational Oncology · doi:10.1007/s12094-024-03654-7 · Cited by 2 · see citing works
- Authors
- Fan, Y., Zhao, J., Wang, Q., Huang, D., Li, X., Chen, J., Fang, Y., Duan, J., Zhou, C., Hu, Y., Yang, H., Hu, Y., Zhou, J., Lin, X., Wang, L., Wang, Z., Xu, Y., Zhang, T., Shi, W., Zou, J., & Wang, J.
- Affiliations
- Zhejiang Cancer Hospital (CN)
- Peking University Cancer Hospital (CN)
- Henan Cancer Hospital (CN)
- Tianjin Medical University Cancer Institute and Hospital (CN)
- First Affiliated Hospital of Zhengzhou University (CN)
- Hunan Cancer Hospital (CN)
- Sir Run Run Shaw Hospital (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Tongji University (CN)
- Chinese PLA General Hospital (CN)
- Zhejiang Taizhou Hospital (CN)
- First Affiliated Hospital Zhejiang University (CN)
- Union Hospital (CN)
- Nanjing Drum Tower Hospital (CN)
- Corresponding author
- Wang, Jie
- ORCID
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 16
- Issue
- 2
- Pages
- 299-309
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W3095089286
- Cited by
- 135
- References
- 39
- Citations by year
- 2026: 7 · 2025: 20 · 2024: 35 · 2023: 22 · 2022: 30 · 2021: 19 · 2020: 1
- FWCI
- 6.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of Thoracic Oncology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- camrelizumab, apatinib, extensive-stage small cell lung cancer, second-line therapy, PD-1 inhibitors, anti-angiogenic therapy, platinum-based chemotherapy, objective response rate, progression-free survival, overall survival, treatment-related adverse events
- MeSH terms
- Humans, Lung Neoplasms, Pyridines, Small Cell Lung Carcinoma, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
